Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategies

23 Nov 2020

Abstract excerpt

BACKGROUND: Prenatal screening for chromosome aneuploidies have constantly been evolving, especially with the introduction of cell-free fetal DNA (cfDNA) screening in the most recent years. This study compares the performance, costs and timing of test results of three cfDNA screening implementation strategies: contingent, reflex and primary. METHODS: We modelled enhanced first trimester screening (eFTS) as the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fetal and Pediatric Neurological Disorders
Share to Genomic variations and chromosomal abnormalities
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33228595
DOI: 10.1186/s12884-020-03394-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategiesPMID 33228595Read ↗

Clinical implementation of routine screening for fetal trisomies in the UK NHS : cell‐free DNA test contingent on results from first‐trimester combined testSemantic proximity Read ↗

Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot studySemantic proximity Read ↗

Contingent first‐trimester screening for aneuploidies with cell‐free DNA in a Danish clinical settingSemantic proximity Read ↗

First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testingSemantic proximity Read ↗

Cell‐free fetal <scp>DNA</scp> screening in the USA: a cost analysis of screening strategiesSemantic proximity Read ↗

First‐trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell‐free DNA testingSemantic proximity Read ↗

An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy PopulationSemantic proximity Read ↗

The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysisSemantic proximity Read ↗

Screening Performance and Costs of Different Strategies in Prenatal Screening for Trisomy 21Semantic proximity Read ↗

The price of performance: a cost and performance analysis of the implementation of cell‐free fetal DNA testing for Down syndrome in Ontario, CanadaSemantic proximity Read ↗

<scp>UK NHS</scp> pilot study on cell‐free <scp>DNA</scp> testing in screening for fetal trisomies: factors affecting uptakeSemantic proximity Read ↗

Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.